Varenicline (DrugBank: Varenicline)
2 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 5 |
| 18 | 脊髄小脳変性症（多系統萎縮症を除く。） | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04403399 (ClinicalTrials.gov) | June 29, 2017 | 21/5/2020 | Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3 (UdallP3) | Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3 | Parkinson's Disease | Drug: Varenicline;Other: Evaluation by Investigator;Other: Placebo | University of Michigan | NULL | Completed | 45 Years | N/A | All | 33 | Phase 2 | United States |
| 2 | NCT02933372 (ClinicalTrials.gov) | October 5, 2015 | 6/4/2016 | Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3 | Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Projects #3 | Parkinson's Disease | Drug: Varenicline;Radiation: [18-Fluorine] Flubatine PET Scan;Other: Evaluation by Investigator | University of Michigan | NULL | Completed | 45 Years | N/A | All | 25 | Phase 2 | NULL |
| 3 | NCT02473562 (ClinicalTrials.gov) | May 2013 | 12/6/2015 | Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease | Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study | Parkinson's Disease | Drug: Varenicline;Drug: Placebo (for varenicline) | VU University Medical Center | Centre for Human Drug Research, Netherlands | Terminated | N/A | N/A | All | 22 | Phase 4 | Netherlands |
| 4 | EUCTR2012-001530-34-NL (EUCTR) | 09/08/2012 | 09/08/2012 | Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s Disease | Varenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study - Vareniciline for Excessive daytime Sleepiness in PArkinson’s disease (VESPA) | Idiopathic Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Champix INN or Proposed INN: VARENICLINE Other descriptive name: VARENICLINE TARTRATE | VU University Medical Center | Center Human Drug Research | Not Recruiting | Female: yes Male: yes | 32 | Phase 3 | Netherlands | ||
| 5 | NCT01341080 (ClinicalTrials.gov) | December 28, 2010 | 21/4/2011 | Varenicline for Gait and Balance Impairment in Parkinson Disease | Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease | Parkinson Disease | Drug: Varenicline;Drug: Sugar pill | Rush University Medical Center | NULL | Completed | 40 Years | 90 Years | All | 40 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000011560 | 2013/08/30 | 26/08/2013 | Trial of varenicline (Champix) for the treatment of spinocerebellar degeneration | spinocerebellar degeneration (SCD) | [High-dose Group] Oral administration of varenicline 1-7 days 0.5 mg/day 8-14 days 1.0mg/day 15-21 days 1.5mg/day 22-56 days 2.0 mg/day 57-63 days 1.0 mg/day 64-70 days 0.5 mg/day 71-84 days Wash-out period 85-154 days 0.5 mg/day [Low-dose Group] Oral administration of varenicline 1-70 days 0.5 mg/day 71-84 days Wash-out period 85-91 days 0.5 mg/day 92-98 days 1.0mg/day 99-105 days 1.5mg/day 106-140 days 2.0 mg/day 141-147 days 1.0 mg/day 148-154 days 0.5 mg/day | Niigata University | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 40 | Phase 1;Phase 2 | Japan |